在STXBP1相关疾病中,早期的发作和发作
Kim M Thalwitzer1,2,3,4, Julie Xian1,2,3,5, Danielle deCampo2,5,6
1Division of Neurology, Children's Hospital of Philadelphia, USA.
medRxiv : the preprint server for health sciences
|July 10, 2023
概括
在STXBP1疾病中早期的发作不会增加患发作的风险. 某些抗发作药物 (ASM),如克洛巴赞和莱维他,在治疗方面表现出有效性.
科学领域:
- 遗传学和神经学 遗传学和神经学
- 儿科症 儿科症
背景情况:
- STXBP1变种与早期发作的有关,通常包括性.
- 早期发作和抗发作药物 (ASM) 对发作发作的发展和轨迹的影响尚不清楚.
- 这种知识差距阻碍了对STXBP1相关的有效治疗策略和临床试验设计.
研究的目的:
- 量化分析STXBP1相关疾病和早期患者的史和ASM反应.
- 为了确定早期的发作或特定的ASM是否会增加患发作的风险.
- 为了确定ASM有效的管理发作在这个人群.
主要方法:
- 对61名STXBP1相关患者每周间隔的发作和药物治疗史的回顾性分析,发病时间在生命的第一年内.
- 对纵向发作模式和对各种ASM的反应进行定量评估.
- 统计分析以评估发生发作的风险和ASM疗效.
主要成果:
- 在患有新生儿或婴儿早期发作的人群中,患发作的风险并没有增加.
- 没有发现ASM增加了先前发作后发生发作的风险.
- 曾经有过的人,患有耐性发作的风险更高.
- 与其他ASM相比,克罗纳泽巴姆,克罗巴萨姆,托皮拉玛和 levetiracetam在减少发作频率或实现发作自由方面更有效.
结论:
- 在STXBP1疾病中早期的发作似乎不会增加患发作的风险.
- 某些ASM,包括clobazam和 levetiracetam,在治疗发作中表现出有效性.
- 这些发现为与STXBP1变异相关的生命早期患者的向治疗和预后提供了关键的基线数据.
更多相关视频
06:58Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
Published on: June 25, 2016
19.2K
10:58TMS: Using the Theta-Burst Protocol to Explore Mechanism of Plasticity in Individuals with Fragile X Syndrome and Autism
Published on: December 28, 2010
17.0K
相关概念视频
01:13Seizures: Classification
426
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
426
01:24Arteries of the Lower Limbs
215
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
215
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
349
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
349
01:20Antiepileptic Drugs: Potassium Channel Activators
215
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
215
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
467
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
467
01:14Antiepileptic Drugs: Glutamate Antagonists
427
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
427